ArticleFrontiers in medicine2026

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.

Qiuting Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.